VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Mersana Therapeutics Executive Compensation (FY24)

MRSN · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Michael Huber
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Mersana Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (DEF 14A): April 29, 2025
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Mersana Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
239 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Huber: $2,601,249 → $1,613,754 (38.0% lower)
CEO pay ratio: 12:1 → 5:1 (58.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Mersana Therapeutics' chief executive and what were they paid?
Michael Huber was paid $1,613,754 in total compensation as President and Chief Executive Officer for fiscal 2024. Huber's total was 38.0% lower than the $2,601,249 reported for fiscal 2023.
Which companies are in Mersana Therapeutics' peer group?
The disclosed peer group names Adicet Bio, Inc., Black Diamond Therapeutics, Inc., C4 Therapeutics, Inc., Century Therapeutics, Inc. and Cue Biopharma, Inc., among others.
What is Mersana Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 5:1 for fiscal 2024, against median employee compensation of $316,460.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anna Protopapas
Former President and Chief Executive Officer
◇—◇◇◇—◇◇
Arvin Yang
Former Senior Vice President, Chief Medical Officer
◇—◇◇◇—◇◇
Brian DeSchuytner
Senior Vice President, Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Timothy Lowinger
Senior Vice President, Chief Science and Technology Officer
◇—◇◇◇—◇◇
Mohan Bala
Senior Vice President, Chief Development Officer
◇◇◇◇◇——— not reconciled
Alejandra Carvajal
Senior Vice President, Chief Legal Officer
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anna Protopapas
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Michael Huber
President and Chief Executive Officer
◇—◇◇◇—◇◇
Arvin Yang
Former Senior Vice President, Chief Medical Officer
Departed during or after this year
◇—◇◇——◇◇
Brian DeSchuytner
Senior Vice President, Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Timothy Lowinger
Senior Vice President, Chief Science and Technology Officer
◇—◇◇◇—◇◇
Alejandra Carvajal
Senior Vice President, Chief Legal Officer
◇—◇◇◇—◇◇
Mohan Bala
Senior Vice President, Chief Development Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Huber
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian DeSchuytner
Senior Vice President, Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Mohan Bala
Senior Vice President, Chief Development Officer
◇—◇◇◇—◇◇
Timothy Lowinger
Senior Vice President, Chief Science and Technology Officer
◇—◇◇◇—◇◇
Alejandra Carvajal
Senior Vice President, Chief Legal Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alejandra CarvajalRSU◇——◇——◇
Alejandra CarvajalOPTION◇——◇—◇◇
Brian DeSchuytnerOPTION◇——◇—◇◇
Brian DeSchuytnerRSU◇——◇——◇
Martin HuberRSU◇——◇——◇
Martin HuberOPTION◇——◇—◇◇
Mohan BalaRSU◇——◇——◇
Mohan BalaOPTION◇——◇—◇◇
Timothy B. LowingerRSU◇——◇——◇
Timothy B. LowingerOPTION◇——◇—◇◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Martin HuberOption◇—◇9/10/2033
RSU◇◇——
Option◇—◇1/14/2034
RSU◇◇——
Mohan BalaOption◇—◇1/14/2034
Option◇—◇1/12/2033
RSU◇◇——
Option◇—◇10/24/2031
RSU◇◇——
RSU◇◇——
Brian DeSchuytnerOption◇—◇1/14/2034
Option◇—◇1/12/2033
RSU◇◇——
Option◇—◇1/13/2032
RSU◇◇——
RSU◇◇——
Option◇—◇1/14/2031
RSU◇◇——
Timothy LowingerOption◇—◇1/14/2034
Option◇—◇1/12/2033
RSU◇◇——
RSU◇◇——
Option◇—◇1/13/2032
RSU◇◇——
Option◇—◇1/14/2031
RSU◇◇——
Alejandra CarvajalOption◇—◇1/14/2034
Option◇—◇1/12/2033
RSU◇◇——
RSU◇◇——
Option◇—◇4/25/2031
Option◇—◇1/13/2032
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Mott
Board chair
◇—◇———◇
Lawrence M. Alleva
◇—◇———◇
Willard Dere, M.D
◇—◇———◇
Kristen M. Hege, M.D
◇—◇———◇
Andrew A. F. Hack, M.D., Ph.D
◇—◇———◇
Allene M. Diaz
◇—◇———◇
Anna Protopapas
◇—◇———◇
Martin Huber, M.D served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.
Stock ownership guideline: Set robust executive officer and non-employee director stock ownership guidelines

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Adicet Bio, Inc. ACET
  • Black Diamond Therapeutics, Inc. BDTX
  • C4 Therapeutics, Inc. CCCC
  • Century Therapeutics, Inc. IPSC
  • Cue Biopharma, Inc. CUE
  • CytomX Therapeutics, Inc. CTMX
  • Fate Therapeutics, Inc. FATE
  • Foghorn Therapeutics, Inc. FHTX
  • IGM Biosciences, Inc. IGMS
  • Ikena Oncology, Inc. symbol not shown
  • Inovio Pharmaceuticals, Inc. INO
  • iTeos Therapeutics, Inc. ITOS
  • Monte Rosa Therapeutics, Inc. GLUE
  • Omega Therapeutics, Inc. symbol not shown
  • Prelude Therapeutics Incorporated PRLD
  • Pyxis Oncology, Inc. symbol not shown
  • Scholar Rock Holding Corporation SRRK
  • Tango Therapeutics, Inc. TNGX
  • TScan Therapeutics, Inc. TCRX
  • Verastem, Inc. VSTM
  • Vor Biopharma, Inc. VOR
  • Werewolf Therapeutics, Inc. HOWL
  • Zymeworks, Inc. ZYME

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Michael Huber (President and Chief Executive Officer), FY2024 total compensation $1,613,754 (base salary $632,500) [exec_comp, SEC accession 0001104659-25-040448, filed 2025-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Mersana Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Mersana Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Mersana Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Mersana Therapeutics' disclosed peer group is defensible, who names Mersana Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
239 figures on this page, cited to the filing that reported them.
239 cited to the filing

Documents cited

  1. 0001104659-25-040448
    2024 Summary Compensation Table · Grants of Plan-Based Awards · Non-Employee Director Compensation · Outstanding Equity Awards at Fiscal Year-End Table · and 1 more section
  2. 0001104659-24-052235
    2023 Summary Compensation Table
  3. 0001104659-23-051856
    2022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Mersana Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/MRSN (accessed 2026).
Short form: data: Velarion

The Mersana Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Mersana Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Mersana Therapeutics discloses

The companies named in MRSN's own disclosed peer group.

Adicet Bio, Inc.Black Diamond Therapeutics, Inc.C4 Therapeutics, Inc.Century Therapeutics, Inc.Cue Biopharma, Inc.CytomX Therapeutics, Inc.Fate Therapeutics, Inc.Foghorn Therapeutics, Inc.IGM Biosciences, Inc.Inovio Pharmaceuticals, Inc.iTeos Therapeutics, Inc.Monte Rosa Therapeutics, Inc.Prelude Therapeutics IncorporatedScholar Rock Holding CorporationTango Therapeutics, Inc.TScan Therapeutics, Inc.Verastem, Inc.Vor Biopharma, Inc.Werewolf Therapeutics, Inc.Zymeworks, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy